PL366317A1 - Zastosowanie nadekspresji podjednostki alfa 4 lamininy jako diagnostycznego i prognostycznego wskaźnika nowotworu złośliwego - Google Patents

Zastosowanie nadekspresji podjednostki alfa 4 lamininy jako diagnostycznego i prognostycznego wskaźnika nowotworu złośliwego

Info

Publication number
PL366317A1
PL366317A1 PL01366317A PL36631701A PL366317A1 PL 366317 A1 PL366317 A1 PL 366317A1 PL 01366317 A PL01366317 A PL 01366317A PL 36631701 A PL36631701 A PL 36631701A PL 366317 A1 PL366317 A1 PL 366317A1
Authority
PL
Poland
Prior art keywords
diagnostic
malignant tumor
prognostic indicator
laminin alpha
subunit overexpression
Prior art date
Application number
PL01366317A
Other languages
English (en)
Inventor
Julia Y. Ljubimowa
Alexander V. Ljubimov
Keith L. Black
Original Assignee
Cedars-Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars-Sinai Medical Center filed Critical Cedars-Sinai Medical Center
Publication of PL366317A1 publication Critical patent/PL366317A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL01366317A 2000-12-19 2001-12-19 Zastosowanie nadekspresji podjednostki alfa 4 lamininy jako diagnostycznego i prognostycznego wskaźnika nowotworu złośliwego PL366317A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/741,550 US20020155440A1 (en) 2000-12-19 2000-12-19 Using overexpression of laminin alpha 4 subunit as a diagnostic and prognostic indicator of malignant tumors

Publications (1)

Publication Number Publication Date
PL366317A1 true PL366317A1 (pl) 2005-01-24

Family

ID=24981166

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01366317A PL366317A1 (pl) 2000-12-19 2001-12-19 Zastosowanie nadekspresji podjednostki alfa 4 lamininy jako diagnostycznego i prognostycznego wskaźnika nowotworu złośliwego

Country Status (7)

Country Link
US (1) US20020155440A1 (pl)
EP (1) EP1356294A2 (pl)
IL (1) IL156541A0 (pl)
NO (1) NO20032781L (pl)
PL (1) PL366317A1 (pl)
WO (1) WO2002059610A2 (pl)
ZA (1) ZA200305097B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
US7877273B2 (en) * 2002-01-08 2011-01-25 Fredric David Abramson System and method for evaluating and providing nutrigenomic data, information and advice
WO2004048548A2 (en) * 2002-11-25 2004-06-10 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US20050053958A1 (en) * 2002-11-25 2005-03-10 Roth Richard B. Methods for identifying risk of breast cancer and treatments thereof
AU2003293130A1 (en) * 2002-11-25 2004-06-18 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US20050272043A1 (en) * 2003-07-24 2005-12-08 Roth Richard B Methods for identifying risk of breast cancer and treatments thereof
JP4567683B2 (ja) * 2003-09-12 2010-10-20 セダーズ−シナイ メディカル センター ヒトグリオームを阻害するための、ラミニン−８発現のアンチセンス阻害
JP5008981B2 (ja) * 2003-12-05 2012-08-22 アロジーン， インコーポレイテッド ポリリンゴ酸ベースの多機能性薬物送達システム
US8911717B2 (en) 2003-12-05 2014-12-16 Cedars-Sinai Medical Center Polymalic acid-based multifunctional drug delivery system
US20050227225A1 (en) * 2004-04-07 2005-10-13 Roche Molecular Systems, Inc. Stabilization of biomolecules in samples
CA2567973A1 (en) * 2004-05-27 2005-12-15 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
CA2661633A1 (en) * 2006-09-06 2008-03-13 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
US8530415B2 (en) * 2008-01-30 2013-09-10 Histogen, Inc. Repair and/or regeneration of cells with a composition produced by culturing fibroblast cells under hypoxic conditions
US8535913B2 (en) * 2008-01-30 2013-09-17 Histogen, Inc. Soluble composition for promoting hair growth produced by hypoxic culture of fibroblasts cells
US8524494B2 (en) 2008-01-30 2013-09-03 Histogen, Inc. Low oxygen tension and BFGF generates a multipotent stem cell from a fibroblast in vitro
CA2714387C (en) * 2008-01-30 2018-06-19 Histogen, Inc. Extracellular matrix compositions
CA2716357A1 (en) * 2008-03-05 2009-09-11 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
RU2393773C1 (ru) * 2009-04-20 2010-07-10 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ УЧРЕЖДЕНИЕ РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ВЫСОКОТЕХНОЛОГИЧНОЙ МЕДИЦИНСКОЙ ПОМОЩИ (ФГУ "РНЦРХТ Росмедтехнологий") Способ прогнозирования продолжительности жизни больных глиальными опухолями головного мозга
CN102482698B (zh) * 2009-07-10 2018-09-25 希斯托金公司 条件培养基和来自低氧含量条件下培养的细胞的胞外基质组合物
EP2509421B1 (en) 2009-12-10 2020-02-05 Cedars-Sinai Medical Center Drug delivery of temozolomide for systemic based treatment of cancer
RU2433410C2 (ru) * 2009-12-25 2011-11-10 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ прогнозирования развития направленности патологического процесса у больных с опухолями головного мозга
RU2441599C1 (ru) * 2010-09-09 2012-02-10 Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (ГУ МОНИКИ им. М.Ф. Владимирского) Способ выбора тактики лечения больных с глиомами низкой степени злокачественности
US9623041B2 (en) 2010-12-30 2017-04-18 Cedars-Sinai Medical Center Polymalic acid-based nanobiopolymer compositions
EP2694117A4 (en) * 2011-04-06 2014-06-11 Cedars Sinai Medical Center IMAGING NANOCONJUGATES BASED ON POLYMALE ACID
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5905027A (en) * 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
US20020076736A1 (en) * 2000-05-12 2002-06-20 Findell Paul R. Methods of affecting laminin 5 processing

Also Published As

Publication number Publication date
NO20032781L (no) 2003-08-18
IL156541A0 (en) 2004-01-04
US20020155440A1 (en) 2002-10-24
EP1356294A2 (en) 2003-10-29
ZA200305097B (en) 2004-08-12
WO2002059610A3 (en) 2003-08-14
NO20032781D0 (no) 2003-06-18
WO2002059610A2 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
PL366317A1 (pl) Zastosowanie nadekspresji podjednostki alfa 4 lamininy jako diagnostycznego i prognostycznego wskaźnika nowotworu złośliwego
IS2808B (is) Mótefnasameindir sem eru með sérvirkni fyrir æxlisdrepboða alfa í mönnum og notkun þeirra
EP2230319A3 (en) Gene expression markers for breast cancer prognosis
DE60020367D1 (de) Luftdurchlässige bekleidung zur komfortverbesserung des menschlichen körper
DE69923520D1 (de) Körperfettmessgerät mit körpergrössenanzeige
EP1037964A4 (en) COMPETITIVE EXCLUSION CULTURE FOR PIGS
NO20003807L (no) <alfa>-ketoamidinhibitorer av 20S proteasome
DE59906199D1 (de) Elastischer bremsenkörper
DE60017449D1 (de) Dünn-bis-nass strukturen zur aufnahme von körperflüssigkeiten
NO20014223D0 (no) Fremgangsmåte for diagnostisering og overvåkning av maligne brystkarsinoma
EP1608964A4 (en) CREATING AN EXPRESSION PROFILE OF TUMORS
DE60005423D1 (de) Unterfütterungsmaterial für Zahnprothesen
DK1163256T3 (da) Hemihydrat af 16.alfa.-bromepiandrosteron
GB0125451D0 (en) The backing up of data
IL155412A0 (en) Diagnostic indicator of thymic function
NO20020885D0 (no) <alfa>v<beta>3-integrininhibitorer
AU2002308807A8 (en) The measuring instrument of the depth of water
DE60030708D1 (de) Beschichtete Hartmetallkörper
AU2002218977A1 (en) Novel marker for the diagnosis and therapy of tumours
DE60105079D1 (de) Informationsempfänger mit Standortübermittlung des Empfängers
FI4860U1 (fi) Reaktorin sydän
NO20010280L (no) <Alfa>-aminosyrefenylesterderivater
AU2003233635A8 (en) Diagnostic indicator of sjogren's syndrome
ES1045471Y (es) Aparato de ondas de d'arsonval rectificadas.
RU2000120594A (ru) Фрикционная накладка

Legal Events

Date Code Title Description
VOID Decisions declaring the decisions on the grant of the patent lapsed